Kazia Therapeutics Limited KZIA

KZIA Company Overview

Kazia Therapeutics Limited is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies, primarily in the field of oncology. The company operates within the biotechnology and pharmaceutical research industries, with a strategic emphasis on difficult-to-treat cancers that have high unmet medical need. Kazia does not generate material commercial revenue and is primarily funded through equity financing and strategic partnerships.

Kazia’s core value is derived from its oncology drug development pipeline, led by paxalisib, a small-molecule PI3K/mTOR pathway inhibitor, and Cantrixil, a late-preclinical oncology asset. The company targets specialist oncology markets, particularly neuro-oncology and gynecologic cancers, and positions itself as a developer of differentiated therapies for orphan or underserved cancer indications. Kazia was founded in 1996 in Australia and has evolved from a diversified biotech into a focused oncology drug developer, listing its American Depositary Shares on the Nasdaq to access U.S. capital markets.